Cohance Lifesciences Share Price Edges Up to ₹460.85: What Is Driving COHANCE Today, and the Levels That Matter

Why COHANCE is being traded today

The in focus story around Cohance Lifesciences (COHANCE) has the stock at ₹460.85, +0.55% on the session, with the NSE board read at 12:05 am IST on 4 September 2026. What the tape shows: the move is inside the stock's usual daily range, so the tape is treating the story as information rather than as a reason to reprice.

The story in five lines

• Where it trades: Cohance Lifesciences is at ₹460.85, +2.55 (+0.55%) versus the previous close of ₹460.85.
• Why it is moving: an in-focus story — 2 business desks filed on the company in the last few hours.
• Today's band: ₹457.80 to ₹464.75, against an open of ₹462.00 — the stock has given up its opening print.
• Twelve-month context: 55.64% below the ₹1,039 high and 72.80% above the ₹267 low, so the stock sits in the middle part of its own range.
• Participation: turnover is running at 0.3x the twenty-day average, which is ordinary flow — the move lacks a volume endorsement so far.
• What to watch: an exchange filing from the company itself, since headline-driven moves without a disclosure behind them tend to fade within a session or two.

Why Cohance Lifesciences is on the desks today

Cohance Lifesciences is one of the most-mentioned names on the business wires right now — run by 2 publishers, with the headlines linked below. When several desks run the same company on the same day, the flow that follows is usually driven by attention rather than by a single disclosure, so the price move needs volume behind it to mean anything.

Live price snapshot

What it means when several desks run the same name

2 publishers filed on Cohance Lifesciences in the last few hours without a single dominant disclosure driving it. Clustered coverage of this kind is usually attention rather than information: a screen result, a sector read-across, or a follow-up to something filed earlier in the week. Attention brings order flow, but order flow without a disclosure behind it decays.

The way to separate the two is participation. A move on turnover at or above the stock's own recent average means positions are changing hands and the level is likely to hold. The same move on thin volume is a handful of trades and reverses easily, which is why the volume column deserves as much attention as the percentage change.

Cohance Lifesciences is at ₹460.85, +2.55 (+0.55%), between ₹457.80 and ₹464.75 on the day, on 0.3x its twenty-day average volume.

Reading today's session

Cohance Lifesciences has traded between ₹457.80 and ₹464.75 in this session against an open of ₹462.00 and a previous close of ₹460.85. That is a band of ₹6.95, or 1.51% of the current price — an ordinary day's spread, so the move is orderly rather than disorderly.

Trading below the open at ₹462.00 puts everyone who bought the first print underwater, and that cohort is the first source of supply on any bounce — which is why sessions that lose the open rarely close on the high.

In market-structure terms this is a continuation session, so the prior trend remains the base case until a level breaks.

The headlines behind this post

Headlines are listed for context and link straight to the publisher. The prices, ranges and tables on this page are read independently from exchange data at the timestamp shown.

• Cohance Lifesciences to invest USD 18 mn in NJ Bio, Aruka Bio — Economic Times
• Cohance Lifesciences to invest $18 million in NJ Bio, Aruka Bio — The Hindu BusinessLine

How the stock has performed

What the returns table is saying

Over the last week Cohance Lifesciences has slipped -0.32% and over the month +8.46%. The two horizons pointing in opposite directions is the signature of a counter-trend move — the shorter reading is either an early turn or a pullback inside the bigger trend, and volume is what separates the two.

The twelve-month return of -49.08% is the context long-term holders judge the stock on. A drawdown of this size over a year means the market has been repricing something structural, so any recovery needs evidence in the numbers, not just a bounce.

Reading the price against its own ranges

Over the last twelve months the price has covered ₹267 to ₹1,039. The current level is 25% of the way through that band, 55.64% below the 52-week high and 72.80% above the 52-week low. A mid-range price means neither the bulls nor the bears own the trend yet; the twelve-month extremes are the levels that decide which way the range resolves.

Traded quantity of 5,40,229 shares is 0.35x the 20-day average of 15,64,212. Turnover this far below normal means the move is being made by very few hands, so the level is easier to reverse and worth treating as provisional.

What to watch next

For this in focus story specifically, watch an exchange filing from the company itself, since headline-driven moves without a disclosure behind them tend to fade within a session or two. On the chart, the ₹464.75 high and ₹457.80 low of this session are the reference levels — a higher low in the next session turns a headline reaction into a trend, a break of today's low usually voids it. Participation is the third check: the move needs turnover at or above the stock's own 20-day average of 15,64,212 shares to be read as positioning rather than a squeeze.

So what should shareholders do with this?

For a trader, this is a low-information session: the move sits inside the stock's normal daily spread, so there is no edge in chasing it. Waiting for a close outside ₹457.80–₹464.75 is the cheaper way to be positioned.

For a long-term shareholder, one session tells you very little. The stock is 55.64% off its twelve-month high, so the more useful exercise is comparing that drawdown with the change in earnings over the same period: price falling faster than profits is an opportunity, the reverse is a warning.

On risk: this report is a reading of live exchange data at a point in time, and intraday levels change. Position sizing — not conviction about the story — is what determines the outcome of a trade built on a headline, and averaging into a falling price without a change in the underlying facts is how a trade becomes an unintended long-term holding.

Where that leaves the stock

Cohance Lifesciences is being bought on an in-focus story, and at ₹460.85 the move is not yet backed by turnover above its own average, which is the version of a rally that tends to fade. The day's ₹457.80–₹464.75 band is the frame for the next session, and an exchange filing from the company itself is what resolves the story either way.

Where to track COHANCE next

Live price, charts and technicals stay on the Cohance Lifesciences stock page, and every filed quarter is tabulated on its quarterly results page. Both pages refresh from the exchange feed through the session, so they carry a later reading than this report once the market has moved on.

Frequently asked questions

What is the Cohance Lifesciences share price today?

Cohance Lifesciences (COHANCE) last traded at ₹460.85, +2.55 (+0.55%) against the previous close of ₹460.85, read from the NSE board at 12:05 am IST on 4 September 2026.

Why is Cohance Lifesciences in the news today?

2 business publishers ran headlines on the company in the last session — a in focus story. Their reports are linked above; the levels and tables here are read independently from exchange data.

What is the 52-week high and low of COHANCE?

Over the last twelve months COHANCE has traded between a low of ₹267 and a high of ₹1,039, computed from the adjusted daily series.

Is COHANCE up or down today?

COHANCE gained +0.55% in this session, trading between ₹457.80 and ₹464.75 against an open of ₹462.00.

Key takeaways

• Last price: ₹460.85 (+0.55%) — higher at the time of writing
• Day range: ₹457.80 – ₹464.75
• 52-week high: ₹1,039

About this report

Every figure on this page is read from a primary source at the timestamp shown — exchange boards for equities and indices, the exchange bid book for IPOs, published association rates for bullion, and consolidated exchange quotes for crypto — with no estimation or third-party commentary. Historical fields such as trailing returns and 52-week extremes are computed on the adjusted daily series so splits and bonuses do not create false gaps. A timestamp outside market hours reflects the last traded or last published value, not a live tick.

Related live pages

• Cohance Lifesciences share price
• Cohance Lifesciences quarterly results
• Stocks in news
• Top gainers
• Market dashboard

Sources

• NSE live board data via our exchange data feed
• Headline attribution links above point to the original publishers
• TrendRipperX Cohance Lifesciences stock page

“This report is generated automatically from live exchange and official association data at the time stamped above. Prices move continuously — verify on the source before acting. Nothing here is investment advice.”